The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
Open accessAbstract
Ten patients with prostatic carcinoma--six with stage C and four with stage D disease--were treated for 6 weeks to 12 months with agonistic analogues of luteinizing hormone-releasing hormone (LH-RH). [D-Trp6]LH-RH was given subcutaneously once daily at a dose of 100 microgram and [D-Ser(But)6]des-GlyNH2(10)-LH-RH ethylamide (HOE 766) was given subcutaneously (50 microgram once daily) or intranasally (500 microgram twice daily). In all patients, mean plasma testosterone levels showed a 75% suppression by the third week of treatment and remained low thereafter. This was followed by a decrease or normalization of plasma acid phosphatase levels by the second month of treatment and a 47% decrease in serum alkaline phosphatase by the 10th week of treatment in all but one patient. In patients with stage C disease presenting with prostatism or urinary outflow obstruction, there was a noticeable clinical improvement. In two such patients, a decrease in the size of the prostate was confirmed by ultrasonography. In patients with stage D disease manifested by diffuse bone metastases, there was relief of bone pain, and in one patient treated for greater than 12 months the improvement was documented by radioisotope bone imaging. It is concluded that superactive agonistic LH-RH analogues hold promise as therapeutic agents in patients with androgen-sensitive prostatic adenocarcinoma. Furthermore, the analogous of LH-RH may be used to assess the responsiveness of patients to surgical castration. Long-term administration of LH-RH analogues could become an alternative to surgical castration and estrogen therapy for the treatment of hormone-dependent prostatic carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linde, R., Doelle, G. C., Alexander, N., Kirchner, F., Vale, W., Rivier, J., & Rabin, D. (1981) · New England Journal of Medicine · doi:10.1056/nejm198109173051203 · Cited by 290
CROWLEY, W. F., COMITF, F., VALE, W., RIVIER, J., LORIAUX, D. L., & CUTLER, G. B. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-2-370 · Cited by 274
Radioimmunoassay of plasma estrone and estradiol
Mikhail, G., Wu, C. H., Ferin, M., & Vande Wiele, R. L. (1970) · Steroids · doi:10.1016/s0039-128x(70)80053-8 · Cited by 239
Simultaneous radioimmunoassay of progestins, androgens and estrogens in rat testis
Bélanger, A., Caron, S., & Picard, V. (1980) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(80)90190-9 · Cited by 177
Extra-pituitary inhibition of testicular function by luteinising hormone releasing hormone
Hsueh, A. J. W., & Erickson, G. F. (1979) · Nature · doi:10.1038/281066a0 · Cited by 159
Pituitary Gonadotropin Inhibition by a Highly Active Analog of Luteinizing Hormone-Releasing Hormone
Sandow, J., Rechenberg, W. V., Jerzabek, G., & Stoll, W. (1978) · Fertility and Sterility · doi:10.1016/s0015-0282(16)43461-8 · Cited by 142
Recent Approaches to Fertility Control Based on Derivatives of LH-RH
Schally, A. V., Arimura, A., & Coy, D. H. (1981) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60487-2 · Cited by 87
Self-citationHeber, D., & Swerdloff, R. S. (1980) · Science · doi:10.1126/science.6773142 · Cited by 61
Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man.
Tolis, G., Mehta, A., Comaru-Schally, A. M., & Schally, A. V. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110320 · Cited by 51
Self-citationSéguin, C., Cusan, L., Bélanger, A., Kelly, P. A., Labrie, F., & Raynaud, J. (1981) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(81)90028-9 · Cited by 39
Self-citation
Cited by
Androgen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083
Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology*
Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., & Leung, P. C. K. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0422 · Cited by 1,046
Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
A history of prostate cancer treatment.
Denmeade, S. R., & Isaacs, J. T. (2002) · Nature reviews. Cancer · doi:10.1038/nrc801 · Cited by 591
Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv257 · Cited by 322
Metadata
- Authors
- Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A. T., Comaru-Schally, A. M., & Schally, A. V.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1982-03
- Volume
- 79
- Issue
- 5
- Pages
- 1658-1662
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2022690114
- Cited by
- 368
- References
- 10
- FWCI
- 61.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.